INTRODUCTION {#S1}
============

Botulinum neurotoxins (BoNTs) are the most potent toxins to humans. BoNT exposure inhibits the release of acetylcholine in presynaptic neurons, leading to a flaccid neuromuscular paralysis that causes death by respiratory collapse. There are seven classical BoNT serotypes (designated A through G), with several new BoNT or BoNT-like serotypes identified within the past several years ([@R56]). BoNT/A, /B, /E, and /F are the etiological sources of most cases of endemic human botulism. Although naturally occurring botulism is rare, BoNTs can be misused as a bioweapon and, thus, have been classified as tier 1 select agents by the Centers of Disease Control and Prevention (CDC). BoNT/A and BoNT/B are also increasingly used therapeutically for the treatment of numerous medical conditions, thereby creating the accompanying risk of iatrogenic botulism.

Structurally, each BoNT molecule is composed of a light chain (LC; the protease domain) and a heavy chain (HC) comprised of an N-terminal translocation domain (H~N~) and a C-terminal receptor-binding domain (H~C~). Functionally, H~C~ determines neuronal specificity by recognizing a polysialoganglioside (e.g., GT1b) and a protein receptor, synaptotagmin (Syt) I/II (for BoNT/B, /G, and /DC) or glycosylated synaptic vesicle protein 2 (SV2) (for BoNT/A, /D, /E, and /F), located on the presynaptic membrane ([@R10]; [@R27]; [@R39]; [@R53]; [@R63]). H~C~ of BoNT/B, /G, and /DC additionally carries a hydrophobic loop, termed the H~C~-loop, which interacts with host membrane lipids ([@R54]; [@R65]; [Figure 1A](#F1){ref-type="fig"}). Under acidic conditions, the H~N~ undergoes a pH-induced structural rearrangement and forms a protein channel that delivers the unfolded LC to the cytosol ([@R22]; [@R30]; [@R33]; [@R38]). The translocated LC then cleaves cytosolic SNARE proteins, thereby blocking neurotransmitter release and nerve transmission ([@R2]; [@R7]).

Currently, the only available antitoxin remedies are polyclonal antibodies from horse or human serum, which have known health risks and are in limited supply ([@R49]). Monoclonal antibodies (mAbs) against BoNT/A have been developed under phase I/II clinical trials ([@R20]; [@R43]). Small proteins such as heavy-chain-only camelid antibodies (called VHHs, nanobodies, or single-domain antibodies) and *de novo* designed mini-proteins against the toxins are currently being developed as alternatives ([@R14]; [@R15]; [@R24]; [@R41]; [@R57]). These small proteins have high stability, can be economically produced, display high binding affinity, and have been shown to function effectively as antitoxins in animal models ([@R18]; [@R26]; [@R48]; [@R50]; [@R59]; [@R60]). However, the therapeutic applications of these antitoxins have been limited by a lack of understanding of the molecular mechanisms underlying BoNT neutralization, the extreme potency of BoNTs (*in vivo* lethal blood concentrations at sub-pM), as well as the diverse sequences among different BoNT serotypes and subtypes.

In earlier studies, we found that VHH-based neutralizing agents (VNAs) consisting of VHH heterodimers joined by a flexible peptide linker possessed significantly improved antitoxin potencies ([@R41]). Similar results have been obtained when developing VNAs for other toxins, such as ricin, anthrax, Shiga toxins, and *Clostridium difficile* toxins ([@R26]; [@R48]; [@R50]; [@R59]; [@R60]; [@R62]). We hypothesized that novel heterodimeric VNAs, which are composed of two VHHs connected by a spacer that permits simultaneous binding, could be rationally designed based on structural and mechanistic knowledge of individual VHHs. Such designer VNAs could display greater efficacy due to their substantially improved binding kinetics and possibly complementary neutralizing mechanisms.

Here, we carried out comprehensive structure-function characterization on six neutralizing VHHs that bind non-competitively, three against BoNT/A1 and three against BoNT/B1. Our studies reveal a spectrum of mechanisms by which VHHs attack and neutralize BoNT at different stages of intoxication, such as disrupting receptor binding, inhibiting channel formation, and preventing LC delivery. We then demonstrate that designer VNAs composed of two VHHs with proximal binding epitopes and distinct neutralizing mechanisms have superior potency in a mouse co-intoxication assay over similar VHHs that are unable to bind simultaneously. Together, this study establishes a platform for structure-based rational design of improved antitoxins against BoNTs.

RESULTS {#S2}
=======

Isolation of BoNT/B1-Neutralizing VHHs {#S3}
--------------------------------------

Our initial goal was to develop bivalent VHHs that neutralize the action of both BoNT/A and BoNT/B, which account for 90% of the human botulism cases ([@R9]). We previously reported the characterization of two panels of VHHs selected for binding to BoNT/A1 and BoNT/B1 ([@R41]), including several VHHs capable of neutralizing their toxin target. Although we obtained neutralizing VHHs recognizing non-overlapping epitopes on all three domains of BoNT/A1, we obtained only one neutralizing VHH for BoNT/B1. To seek additional neutralizing BoNT/B-binding VHHs, we obtained a new panel of VHHs selected for binding to catalytically inactive BoNT/B1 (ciBoNT/B1). The phage-displayed VHHs were derived from several immunized alpacas and were selected for binding to plastic-coated ciBoNT/B1 or LC/B or binding to ciBoNT/B1 captured by a non-neutralizing VHH (JEQ-H11). The aa sequences of 13 novel BoNT/B1-binding VHHs are shown in [Figure S1A](#SD1){ref-type="supplementary-material"}. We systematically examined their EC~50~ binding affinity to ciBoNT/B1, mapped the binding epitopes of these VHHs using ELISA against LC/B and H~C~B, and tested their ability to neutralize BoNT/B1 intoxication using primary neurons. All these results are summarized in [Table S1](#SD1){ref-type="supplementary-material"} and [Figure S1B](#SD1){ref-type="supplementary-material"}.

Four Neutralizing VHHs Block BoNT/B1 Binding to Host Receptors {#S4}
--------------------------------------------------------------

Notably, four of the five most potent neutralizing VHHs (JLK-G12, JLO-G11, JLI-G10, and JLI-H11) recognize H~C~B. In our earlier studies, we identified a potent neutralizing VHH (ciA-C2) against BoNT/A1, which binds to the H~C~ domain of BoNT/A1 and prevents its binding to its protein receptor SV2 ([@R64]). But, no neutralizing epitope has been mapped to H~C~B before. To further understand the molecular basis of toxin neutralization by these four H~C~B-binding VHHs, we determined the crystal structures of H~C~B in complex with JLK-G12, JLO-G11, JLI-G10, or JLI-H11 at 2.2 to 3.2 Å resolution ([Table S2](#SD1){ref-type="supplementary-material"}). Structural analysis demonstrated that all four VHHs bind to the C-terminal subdomain (H~CC~) of H~C~B, which harbors the binding sites for BoNT/B's protein receptor Syt and polysialoganglioside ([Figure 1B](#F1){ref-type="fig"}).

VHH JLI-G10 binding to H~C~B buries a molecular surface area of \~974 Å^2^ per molecule (calculated by PDBePISA v1.51) ([Figure 2A](#F2){ref-type="fig"}). The structure of the H~C~B--GD1a (PDB: 4KBB) complex revealed that the polysaccharide head group of a ganglioside makes contacts with a shallow groove in H~C~B composed of a "E~1190~ ... H~1241~ ... ~1260~SXWY~1263~ ... G~1277~" motif, which is also conserved in other BoNT serotypes ([@R6]; [@R32]; [@R46]). We found that the complementarity-determining region 3 (CDR3) of JLI-G10 occupies the same area on H~C~B as GD1a, which should strongly compete for ganglioside binding. Specifically, residue R106 of JLI-G10 interacts with E1190, H1241, and W1262 of H~C~B, and the backbone carbonyl of A104 of JLI-G10 is hydrogen bonded with Y1263 and G1277 of H~C~B. The VHH-H~C~B complex is further strengthened by electrostatic and hydrophobic interactions ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2D](#SD1){ref-type="supplementary-material"}). Consistent with the structural finding, JLI-G10 significantly reduced binding of H~C~B to GT1b-containing liposomes in a co-sedimentation assay ([Figures 2B](#F2){ref-type="fig"} and [S7D](#SD1){ref-type="supplementary-material"}).

Interestingly, JLI-G10 causes a large conformational change in the membrane-binding H~C~-loop (E1245--E1252) on H~C~B by directly binding to the hydrophobic residues I1248 and F1250 ([Figures 2C](#F2){ref-type="fig"} and [S2D](#SD1){ref-type="supplementary-material"}). Prior studies showed that deleting I1248-F1250 in this region potently inhibited the binding of H~C~B to membrane-embedded Syt II, even though these residues are not directly involved in binding the luminal domain of Syt II ([@R17]; [@R54]). It, thus, prompted us to hypothesize that JLI-G10 might also impair the association of H~C~B with the plasma membrane in addition to competing for ganglioside binding. To test this hypothesis, we assessed the ability of the H~C~B--JLI-G10 complex to interact with the soluble GST-Syt II luminal domain (residues 1--61) or a membrane-anchored GST-Syt II (residues 1--90) that carries the transmembrane domain and is solvated in Triton X-100 micelles. The latter was shown to faithfully mimic Syt II insertion in a membranous environment ([@R54]). As expected, JLI-G10 did not disturb H~C~B binding to the soluble GST-Syt II ([Figures 2D](#F2){ref-type="fig"} and [S7E](#SD1){ref-type="supplementary-material"}). However, JLI-G10 completely blocked the binding of H~C~B to GST-Syt II (1--90) embedded in Triton X-100 micelles, even in the presence of co-receptor GT1b ([Figures 2E](#F2){ref-type="fig"} and [S7F](#SD1){ref-type="supplementary-material"}) that should form a cis-complex with Syt II in the detergent micelle to enhance H~C~B binding ([@R23]). These data collectively suggest that JLI-G10 inhibits the binding of BoNT/B1 to neuronal membrane by simultaneously occupying the membrane-binding H~C~-loop and the ganglioside-binding pocket on H~C~B.

The binding sites of JLK-G12 and JLO-G11 on H~C~B partially overlap with the Syt II-binding pocket ([@R27]; [Figures 2F](#F2){ref-type="fig"}, [S2](#SD1){ref-type="supplementary-material"}, and [S3](#SD1){ref-type="supplementary-material"}). Because these two VHHs share a high sequence identity of \~84% and bind to H~C~B in a similar manner (root-mean-square deviation \[RMSD\] = 0.41 Å), we focused on JLK-G12 for further study, which has a slightly bigger interface with H~C~B than JLO-G11 (943 Å^2^ versus 872 Å^2^). Interestingly, JLK-G12 shares similarities with Syt II when recognizing H~C~B. For example, a phenylalanine (F101) in the CDR3 loop of JLK-G12 is inserted into the same hydrophobic pocket on H~C~B that otherwise accommodates F54 of Syt II, which is crucial for high affinity binding of BoNT/B to Syt II ([Figure 2F](#F2){ref-type="fig"}; [@R27]). This mimicry suggests that JLK-G12 neutralizes BoNT/B1 by blocking its binding to Syt. This is supported by the observation that JLK-G12 clearly prevented the binding of H~C~B to GST-Syt II (1--61) ([Figures 2D](#F2){ref-type="fig"} and [S7E](#SD1){ref-type="supplementary-material"}).

Notably, JLK-G12 partly interacts with the H~C~-loop of H~C~B, which suggests that JLK-G12 may also interfere with lipid binding of H~C~B ([Figures S2B](#SD1){ref-type="supplementary-material"} and [S2E](#SD1){ref-type="supplementary-material"}). Consistent with this structural finding, we observed that JLK-G12 inhibited binding of H~C~B to GT1b-containing liposomes in a liposome co-sedimentation experiment, even though it does not directly compete with GT1b binding ([Figures 2B](#F2){ref-type="fig"} and [S7D](#SD1){ref-type="supplementary-material"}). Furthermore, JLK-G12 also inhibited binding of H~C~B to detergent-solvated Syt II (1--90) supplemented with GT1b ([Figures 2E](#F2){ref-type="fig"} and [S7F](#SD1){ref-type="supplementary-material"}). Therefore, JLK-G12 appears to inhibit BoNT/B1 binding to both its neuronal protein receptor Syt and plasma membrane, which leads to potent toxin neutralization.

The neutralizing mechanism of VHH JLI-H11 was initially confusing, because it binds H~C~B in a region that has no known function ([Figures 2G](#F2){ref-type="fig"}, [S2C](#SD1){ref-type="supplementary-material"}, and [S2F](#SD1){ref-type="supplementary-material"}). A detailed structural analysis revealed that the N terminus of JLI-H11 clashes with the N terminus of a fragment of Syt II (residues 44--60) based on the crystal structure of a H~C~B--Syt II complex. It is worth noting that only residues 44 to 60 of Syt II were resolved in this crystal structure, whereas Syt II residues N-terminal to this fragment were not observed due to high structural flexibility ([@R27]). Therefore, we hypothesized that JLI-H11 may clash more severely with Syt II in a region N-terminal to fragment 44--60. Supporting this notion, we found that JLI-H11 partially inhibited H~C~B binding to both soluble Syt II (1--61) and the detergent-solvated Syt II (1--90) ([Figures 2D](#F2){ref-type="fig"}, [2E](#F2){ref-type="fig"}, [S7E](#SD1){ref-type="supplementary-material"}, and [S7F](#SD1){ref-type="supplementary-material"}). As the JLI-H11 epitope does not overlap with the H~C~-loop or the glycolipid-binding pocket of H~C~B, the H~C~B--JLI-H11 complex was able to bind the GT1b-containing liposome and partially interacted with detergent-solvated Syt II supplemented with GT1b ([Figures 2B](#F2){ref-type="fig"}, [2E](#F2){ref-type="fig"}, [S7D](#SD1){ref-type="supplementary-material"}, and [S7F](#SD1){ref-type="supplementary-material"}). Together, these findings suggest that JLI-H11 neutralizes BoNT/B1 by competing with its binding to the protein receptor.

VHH ciA-B5 Blocks Membrane Insertion of BoNT/A1 Translocation Domain {#S5}
--------------------------------------------------------------------

In our earlier work, we obtained a large panel of unique BoNT/A1-binding VHHs recognizing seven non-overlapping epitopes on the toxin ([@R41]). Among these VHHs, ciA-B5, ciA-C2, and ciA-H7 potently neutralized BoNT/A1 intoxication through binding at unique epitopes. VHH ciA-C2, which binds to the H~C~ domain of BoNT/A1, was recently shown to neutralize BoNT/A1 through inhibition of its binding to the protein receptor SV2 ([@R64]). Here, we performed structural analyses on ciA-B5 and ciA-H7, which bind to H~N~ and LC of BoNT/A1, respectively. We also included VHH ciA-D12 as a control for ciA-H7 because ciA-D12 binds to a distinct epitope in LC/A and possesses marginal neutralizing activity in cell-based assays ([@R41]). After extensive crystallization screening trials, we successfully crystallized a hetero-tetrameric complex composed of LCH~N~/A (residues M1 to K871), including both the LC and the H~N~ of BoNT/A1, and all three VHHs in a 1:1:1:1 ratio. The structure of LCH~N~/A--B5--D12--H7 was determined at 2.16-Å resolutions ([Table S2](#SD1){ref-type="supplementary-material"}).

We first focused on the neutralizing mechanism of ciA-B5 that recognizes an epitope on the N-terminal boundary of the rod-like H~N~ ([Figure 3A](#F3){ref-type="fig"}). We found that ciA-B5 inhibited the H~N~A-mediated dye release of calcein-loaded asolectin liposomes by over 85% ([Figure 3B](#F3){ref-type="fig"}) and potently reduced the ability of H~N~A to dissipate valinomycin-induced membrane potential in anionic liposomes in a concentration-dependent manner ([Figure 3C](#F3){ref-type="fig"}). These data demonstrated that ciA-B5 blocks the channel formation of H~N~A, which is a crucial step during BoNT/A intoxication. Interestingly, aa sequence analysis shows that the ciA-B5 epitope on BoNT/A1 (residues 600--616) partially overlaps with a putative channel-forming amphipathic region ([@R33]; [@R35]) (residues 593--686; [Figures 3A](#F3){ref-type="fig"}, [S2G](#SD1){ref-type="supplementary-material"}, [S2J](#SD1){ref-type="supplementary-material"}, and [S4A](#SD1){ref-type="supplementary-material"}). Specifically, M39 and Y103 of ciA-B5 interact with L604, V607, V611, and Y612 of BoNT/A1, and R60 of ciA-B5 forms a salt bridge with D616 of BoNT/A1. Therefore, ciA-B5 may interfere with membrane insertion of its epitope into the membrane during channel formation.

We found that the ciA-B5-bound H~N~A was still able to interact with anionic liposome and showed pH-dependent conformational change ([Figures 3D](#F3){ref-type="fig"}, [S4B](#SD1){ref-type="supplementary-material"}, and [S7L](#SD1){ref-type="supplementary-material"}). This is consistent with the structure showing that the ciA-B5-binding epitope is distant from the "BoNT-switch," which is a motif crucial for membrane association of H~N~A at acidic pH ([@R33]; [Figure S4A](#SD1){ref-type="supplementary-material"}). However, when we pre-incubated H~N~A with liposomes to allow membrane insertion of H~N~A, co-sedimentation of ciA-B5 with liposome-embedded H~N~A was drastically reduced ([Figures 3D](#F3){ref-type="fig"} and [S7M](#SD1){ref-type="supplementary-material"}). This finding suggested that ciA-B5 may inhibit H~N~A from forming a membrane-embedded channel. Previous studies showed that peripherally bound proteins, but not transmembrane or lipid-anchored proteins, could be extracted by either 1 M sodium chloride (pH 4.4), 0.1 M sodium bicarbonate (pH 11), or phosphate-buffered saline (PBS) (pH 7.4) ([@R3]; [@R55]). We found that H~N~A remained bound to liposomes under all these protein extraction conditions, suggesting that H~N~A stably inserts into the liposome. In contrast, about half of the H~N~A--ciA-B5 complex was extracted by alkaline solution at pH 11 and by PBS to a less extent, indicating that binding of the H~N~A--ciA-B5 complex to lipids is partially reversible ([Figures 3E](#F3){ref-type="fig"} and [S7N](#SD1){ref-type="supplementary-material"}). Taken together, these findings demonstrate that ciA-B5 is able to block membrane insertion of the N-terminal region of H~N~A and, thus, channel formation of BoNT/A1.

VHHs ciA-H7 and ciA-D12 Interfere with the Unfolding of the Protease Domain {#S6}
---------------------------------------------------------------------------

VHHs ciA-H7 and ciA-D12 strongly bind the holotoxin through the surface-exposed regions on LC/A ([@R41]). The strong neutralizing capacity of VHH ciA-H7 was not readily explained by its structure because its binding site on LC/A is distant from the SNAP-25 binding pocket or the active site of LC/A and has no known function ([Figures 4A](#F4){ref-type="fig"} and [S4C](#SD1){ref-type="supplementary-material"}). Indeed, ciA-H7 and ciA-D12 did not inhibit cleavage of SNAP-25 by LC/A (residues 2--438) *in vitro* ([Figure S4D](#SD1){ref-type="supplementary-material"}). Therefore, the neutralization activity of ciA-H7 seems to be unrelated to the protease function of LC/A. We noticed that ciA-H7 directly interacts with many secondary structures on LC/A through a very large interface (\~1,170 Å^2^), covering residues in the long helix α5, three surface loops (Loop120, 170, and 250) and α10 of LC/A ([Figures 4A](#F4){ref-type="fig"}, [S2I](#SD1){ref-type="supplementary-material"}, and [S2L](#SD1){ref-type="supplementary-material"}). In contrast, the binding interface for ciA-D12 is smaller (\~778 Å^2^), mainly including residues in the C-terminal loop, the N-terminal loop, and α10 of LC/A. Interestingly, in our earlier study, we found that another VHH (ciA-F12), which is not protective against BoNT/A1 in mouse studies, recognizes LC/A through an even smaller interface (\~684 Å^2^) involving two surface β-hairpins([@R25]; [@R41]; [Figures 4A](#F4){ref-type="fig"} and [S4C](#SD1){ref-type="supplementary-material"}). These structural findings not only explain the higher binding affinity of ciA-H7 in comparison to ciA-D12 and ciA-F12 ([@R41]) but also suggest that ciA-H7 may be superior at stabilizing the structure of LC/A. Because LC must partially unfold upon endosomal acidification before it can pass through the H~N~ channel (\~15 Å diameter) to enter the cytoplasm ([@R30]), agents preventing LC unfolding in endosomes could prevent translocation and, thus, neutralize the toxin. Alternatively, ciA-H7 might interfere with LC interactions with the membrane and the H~N~ chaperone during translocation and, thus, block trans-membrane delivery of LC/A ([@R40]; [@R44]; [@R47]).

We then asked how these VHHs may affect the thermo-stability and low-pH-induced unfolding of LC/A. Using a fluorescence-based thermal shift assay ([Figure 4B](#F4){ref-type="fig"}), we found that the melting temperature (T~m~) of LC/A was significantly increased by 30.9%--34.9% at pH 4--6.5 in the presence of ciA-H7 and 20.1%--25.4% for ciA-D12, whereas ciA-F12 had no effect. We further monitored the effect of these VHHs on low-pH-induced unfolding of LC/A by using a hydrophobic dye, ANS. A large increase in fluorescence at pH below 4.8 was indicative of exposure of hydrophobic surfaces during LC/A unfolding. We found that LC/A unfolding was almost completely inhibited by ciA-H7 and by ciA-D12 to a lesser extent but not by ciA-F12 ([Figure 4C](#F4){ref-type="fig"}). Together, these data demonstrate that ciA-H7 is able to potently prevent LC/A unfolding, which is a prerequisite for membrane translocation of LC/A. VHH ciA-D12 has a weaker ability to prevent LC/A unfolding, which may explain why ciA-D12 is a comparatively poor LC/A neutralizing agent in cell-based assays ([@R41]).

Structure-Based Design of VHH Heterodimers {#S7}
------------------------------------------

In earlier studies, we often observed dramatically increased antitoxin potency when we genetically linked two VHHs and produced them as heterodimeric VNAs ([@R41]). However, these VNAs were designed empirically without knowing the binding sites, neutralizing mechanisms, and their relative positioning of the parental VHHs. Having obtained precise structural information on many high-affinity VHHs against BoNT/A1 and BoNT/B1, we were now able to rationally design a new generation of heterodimeric VNAs, which are composed of two selected VHHs that could bind and/or neutralize toxin synergistically. Specifically, the two parental VHHs in each designer VNAs were carefully selected so that a flexible spacer could be designed based on the distances between their amino or carboxyl termini to allow simultaneous binding to two epitopes on the same toxin molecule. When possible, we paired two VHHs with complementary neutralizing mechanisms. We used the rigid, inflexible portion of VHHs as building blocks, which begin in the framework 1 sequence "QVQLVE..." and end with the framework 4 sequence "...VSS." All pairwise distance estimates between VHHs were calculated from these termini. The flexible spacers engineered to join two VHHs consisted of either GGGGS repeats or poly-glycines, and their spanning lengths can be accurately estimated ([@R13]).

To test this rational design platform, we designed a series of VNAs containing linkers of different lengths that would allow only one VHH to bind at a time or both VHHs to bind simultaneously. In one example, the LC/A-binding ciA-D12, a poorly neutralizing VHH, was found to bind an epitope on BoNT/A1 holotoxin that is spatially proximal to the epitope of ciA-B5, a high-affinity neutralizing VHH binds on H~N~A. As the estimated distance is \~17 Å and \~20 Å in the ciA-D12/ciA-B5 and ciA-B5/ciA-D12 orientations, respectively ([Figure 5A](#F5){ref-type="fig"}; [Table S3](#SD1){ref-type="supplementary-material"}), we designed an 11-aa peptide linker composed of glycine and serine to ensure simultaneous binding of ciA-D12 and ciA-B5 (D12/11/B5). Because the binding sites for ciA-D12 and ciA-B5 are close to each other, making it difficult to design a shorter spacer to preclude simultaneous binding, we constructed another VNA as a control, in which ciA-D12 was linked to ciA-H7 that has comparable neutralization potency as ciA-B5 but a binding site distant from ciA-D12 ([@R41]). These two VHHs were linked with an 11-aa spacer (D12/11/H7), which is too short to permit simultaneous binding.

The second set of VNAs were engineered based on VHHs JLI-G10 and JLK-G12, which bind at nearby sites on H~C~B and block BoNT/B1 recognition of its receptors. We engineered two VNAs with these two VHHs in opposite orientations: (1) JLI-G10 was linked to JLK-G12 (distance \~37 Å) with a 12-aa spacer (G10/12/G12) that should permit simultaneous binding, and (2) JLK-G12 was linked to JLI-G10 (distance \~80 Å) with a short 5-aa spacer (G12/5/G10) to prevent simultaneous binding. A third set of VNA was designed based on JLK-G12 and JLI-H11, which is another H~C~B-binding neutralizing VHH. We designed two heterodimers of these two VHHs in the JLI-H11/JLK-G12 orientation (distance \~61 Å) with either a 20-aa spacer (H11/20/G12) to permit simultaneous binding or a 3-aa spacer (H11/3/G12) that is too short for simultaneous binding ([Figure 5B](#F5){ref-type="fig"}; [Table S3](#SD1){ref-type="supplementary-material"}).

Because these bifunctional VNAs intrinsically have extremely high affinity for their targets, it is infeasible to differentiate simultaneous from non-simultaneous binding of parental VHHs by SPR-based methods. Therefore, we performed size-exclusion chromatography to examine the binding stoichiometry between BoNT domains and VNAs, as VNAs with simultaneous binders should form a monomeric complex with BoNT, whereas VNAs with non-simultaneous binders should cross-link BoNTs to form high-molecular-weight oligomers ([Figure 5](#F5){ref-type="fig"}). We found that D12/11/B5 and LCH~N~/A formed monomeric complexes when these proteins were pre-incubated in 1:1 and 5:1 molar ratios ([Figure 5C](#F5){ref-type="fig"}). Simultaneous binding of these two VHHs was further confirmed by the co-crystal structure of LCH~N~/A in complex with the designer VNA ([Figures S4E](#SD1){ref-type="supplementary-material"}-[S4G](#SD1){ref-type="supplementary-material"}). In contrast, the non-simultaneous binding D12/11/H7 cross-linked LCH~N~/A to form multimeric species with higher molecular weight ([Figure 5C](#F5){ref-type="fig"}, bottom panel). A significant amount of VNAs G10/12/G12 ([Figure 5D](#F5){ref-type="fig"}) and H11/20/G12 ([Figure 5E](#F5){ref-type="fig"}) formed monomeric complexes with H~C~B, indicating simultaneous binding. But their counterparts G12/5/G10 and H11/3/G12, the predicted non-simultaneous binders, only formed oligomeric complexes due to cross-linking of H~C~B ([Figures 5D](#F5){ref-type="fig"} and [5E](#F5){ref-type="fig"}, bottom panels). These data, thus, confirmed that the structure-based design of these VNAs was successful.

Simultaneous Binding VNAs Possess Significantly Improved Antitoxin Potency {#S8}
--------------------------------------------------------------------------

We next compared the *in vivo* potency of selected VNAs in a mouse co-intoxication model, in which fixed amounts of VNAs were pre-mixed with increasing doses of BoNT/A1 or BoNT/B1 and injected into mice, and the mice were monitored for symptoms of intoxication and time to death ([Figures 6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}). We first compared the simultaneous binder D12/11/B5 with a non-simultaneous binder, D12/11/H7. VNA D12/11/B5 (\~40 pmoles) fully protected mice from 100 lethal dose 50 (LD~50~) of BoNT/A1 and delayed death for about 2 days in mice receiving 500--1,000 LD~50~ of toxin, whereas the D12/11/H7-treated mice survived for 1 day when challenged with 100 LD~50~ and displayed little protection at high challenge doses ([Table S3](#SD1){ref-type="supplementary-material"}). Only one parental VHH (ciA-B5 or ciA-H7) could neutralize BoNT/A1 in these two VNAs. We previously reported a VNA (H7/30/B5), in which two strong neutralizing VHHs were connected by a 30-aa peptide linker ([@R41]). But with the new structural information, it is now clear that this peptide linker is too short to allow simultaneous binding of ciA-H7 and ciA-B5. Interestingly, we found that the antitoxin efficacy of D12/11/B5 was comparable to H7/30/B5. This finding suggests that the neutralizing potency of ciA-B5 could be enhanced by a non-neutralizing VHH through synergistic binding in a designer VNA, which could be as potent as a simple addition of two neutralizing VHHs.

We then tested designer VNAs composed of two neutralizing VHHs against BoNT/B1 ([Figure 7](#F7){ref-type="fig"}; [Table S3](#SD1){ref-type="supplementary-material"}). For designer VNAs H11/20/G12 and G10/12/G12 that allow simultaneous binding of parental VHHs, the VNA-treated mice survived a LD~50~ challenge with no or minor signs of botulism, respectively. They partially protected mice when exposed to 5,000 LD~50~ of toxin and significantly delayed death even at 10,000 LD~50~ of toxin. In contrast, the control VNAs H11/3/G12 and G12/5/G10, which contain the same parental VHHs as the above two, provided little or no protection in mice challenged with 1,000 LD~50~ of BoNT/B1. We speculate that such dramatically improved antitoxin potency for H11/20/G12 and G10/12/G12 is caused by both synergistic binding and complementary neutralizing mechanisms of the two parental VHHs. Taken together, these results clearly demonstrate the advantage of the structure-based VNA design platform.

We further evaluated the practical application of these VNAs as potential antitoxins by testing the *in vivo* potency of selected VNAs when they were administered separately from toxins ([Figures S5A](#SD1){ref-type="supplementary-material"} and [S5B](#SD1){ref-type="supplementary-material"}). As a proof of concept, VNAs D12/11/B5 or H11/20/G12 were first administered to mice by tail vein injection, which was followed by giving variable doses of BoNT/A1 or BoNT/B1, respectively, by intraperitoneal injection 5 min after VNA administration. We found that both D12/11/B5 and H11/20/G12 fully protected mice from 100 LD~50~ of the appropriate toxin and delayed death for several days in mice receiving 500--1,000 LD~50~ of the toxin. These two VNAs fully protected mice against 10 LD~50~ of BoNT/A1 and BoNT/B1, respectively, when administered 30 or 60 min prior to toxins ([Figures S5C](#SD1){ref-type="supplementary-material"} and [S5D](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#S9}
==========

BoNTs can be extremely toxic to animals and humans, and the source bacteria are widely distributed in nature and express BoNTs with broad sequence variations. There is a clear unmet need for improved treatments for botulism, which should be safe, economical, and easily manufactured in large amounts. In this paper, we strive to develop a platform to rationally design potent VHH-based antitoxins against BoNTs. Specifically, we first investigated the binding epitopes and neutralizing mechanisms for a selected group of VHHs. Based on these structural and functional information, we further enhanced the potency of these VHHs by rational design of heterodimeric VNAs, which use custom-designed peptide linkers to achieve simultaneous binding of two parental VHHs that have non-overlapping yet closely apposed epitopes ([@R5]; [@R16]).

We revealed two neutralizing mechanisms against BoNT/A1: (1) ciA-B5 blocks the acidic pH-driven insertion of H~N~ into the endosomal membrane, which is required for translocation of LC into the cytosol; and (2) ciA-H7 inhibits the pH-dependent conformational change and translocation of LC. We also reported the creation of a panel of VHHs that bind to BoNT/B1, and we identified three high-affinity, neutralizing VHHs, namely, JLK-G12, JLI-G10, and JLI-H11, which interfere with receptor binding of BoNT/B1. Interestingly, although JLK-G12 and JLI-G10 primarily prevent BoNT/B1 binding to Syt II or ganglioside, respectively, both VHHs also interact with a membrane-binding loop (H~C~-loop) on H~C~B. The newly discovered H~C~-loop is located proximately in between the Syt- and the ganglioside-binding pockets on H~C~B, serving as the third membrane anchoring point for BoNT/B on neuronal cell surface ([@R54]). JLK-G12 and JLI-G10 are unique in a way that they can block membrane binding of BoNT/B by targeting the H~C~-loop. A similar neutralizing mechanism could be applied to antagonize BoNT/G or /DC, as they share similar receptor-recognition mechanisms as BoNT/B ([@R54]; [@R65]). On the other hand, BoNT/A, /HA, and other BoNTs that rely on SV2 as their protein receptor have spatially distant binding sites for SV2 and ganglioside ([@R53]; [@R63]). It remains unknown whether these BoNTs may also have a membrane-binding motif equivalent to the H~C~-loop of BoNT/B that could be targeted by antibodies.

Our designer VNAs display significantly improved antitoxin potencies versus component VHHs. In one example, a poorly neutralizing VHH (ciA-D12), when appropriately linked to a neutralizing VHH (ciA-B5) that binds at an adjacent site, resulted in a VNA that is as potent as a simple addition of two neutralizing VHHs. Combining two neutralizing VHHs in a simultaneous binding designer VNA further improved the overall potency, as demonstrated by H11/G12 and G10/G12 neutralization of BoNT/B1. Despite the short half-life of H11/20/G12 and G10/12/G12 in blood (estimated at 1--2 h), they were as potent as a simple combination of two neutralizing mAbs that inhibit BoNT/B dual-receptor binding at non-overlapping epitopes ([@R12]). Furthermore, we have shown that the potency of VNAs can be further enhanced by including two epitopic tags and co-administering a single anti-tag mAb, which promotes rapid serum clearance of the toxin ([@R41]). Therefore, designer VNAs hold great promise as anti-BoNT therapeutic agents.

The designer VNA strategy could also help to tackle another major obstacles in the development of botulism antitoxins, which is the high sequence diversity within each BoNT serotypes. For example, BoNT/A and /B each have eight distinct subtypes, with additional subtypes likely to be discovered. It is well known that primary sequence differences among BoNT subtypes can impact antibody binding and neutralization properties ([@R52]). We found that the ciA-B5 epitope of BoNT/A is identical among BoNT/A1 and A5--A8 and is \>90% conserved among BoNT/A^2^--A4 ([Figure S6](#SD1){ref-type="supplementary-material"}). Hence, ciA-B5 is likely to bind well to all BoNT/A subtypes. Sequence analysis showed that the JLI-G10, JLK-G12, and JLI-H11 epitopes are moderately conserved among BoNT/B subtypes, suggesting that these VHHs likely have some affinity toward most or all BoNT/B subtypes ([Figure S6](#SD1){ref-type="supplementary-material"}). Therefore, a comprehensive structure-based mapping of antibody binding epitopes on BoNTs is needed to identify more conserved epitopes on BoNTs, which will aid the development of neutralizing antibodies with cross-subtypes or cross-serotype efficacies.

We expect that designer VNAs will have better tolerance to cross-subtype sequence diversity because they recognize a much larger surface on BoNTs than individual VHHs ([@R34]), and the two parental VHHs bind synergistically and could exploit complementary neutralizing mechanisms. In addition, the many co-crystal structures of BoNT--VHH complexes presented here and in the literature lay the foundation for structure-based engineering of VNAs to enhance their neutralizing potencies and broaden reactivity. Taken together, we have established a platform to advance our ability to rapidly and rationally develop novel designer VNAs to prevent and/or treat BoNT intoxication.

STAR★METHODS {#S10}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S11}
---------------------------------------

Further information and requests for resources and reagents should be directed to the Lead Contact, Rongsheng Jin (<r.jin@uci.edu>). All unique/stable reagents generated in this study will be made available on request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

Five alpacas, two juveniles (\~age 1) and three adults including both males and females, all outbred and raised on pasture, were procured from local farm. All studies were carried out in strict accordance with the recommendations delineated in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The procedures used were approved by the Tufts University Institutional Animal Care and Use Committee (IACUC) and were performed under Protocols \#G2011-08 and \#G2017-18.

CD1 Mice (eight week old, female) were purchased from Charles River Laboratories. All procedures were approved by the USAMRICD IACUC and conducted in accordance with the principles stated in the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966 (P.L. 89-544), as amended.

METHOD DETAILS {#S13}
--------------

### Cloning, expression, and purification of recombinant proteins {#S14}

Five alpacas were immunized with purified recombinant catalytically inactive BoNT/B1 holotoxin (ciBoNT/B1) ([@R41]) and/or LC/B by five multi-site subcutaneous (SC) injections at approximate 3-week intervals essentially as described by [@R60]. Blood was obtained for lymphocyte preparation 3--5 days after the fifth immunization, and RNA was prepared from lymphocytes using the RNeasy kit (QIAGEN, Valencia, CA). Three VHH-display phage libraries were prepared from the lymphocyte RNA from either one alpaca or pools of two alpacas, each as described previously by [@R37]. Three different libraries were prepared, each having a complexity of \> 10^7^ independent clones with \> 95% containing VHH inserts.

The phage libraries were panned to select and identify VHHs binding to ciBoNT/B1 using methods essentially as previously described ([@R37]; [@R41]). Some VHHs were obtained by panning on ciBoNT/B1 that had been immobilized either in Nunc Immunotubes or on Costar tissue culture plastic dishes. To select for VHHs binding to native ciBoNT/B1, a further round of panning was performed in which phage from one library was selected for binding to soluble ciBoNT/B1 that had been captured onto Nunc Immunotubes that were first coated with the ciBoNT/B1-binding VHH JEQ-H11 (see [Table S1](#SD1){ref-type="supplementary-material"}). Two rounds of panning, one at low stringency and a second at higher stringency were performed as described by [@R60]. Typically, at least ninety-five random clones from selected populations obtained using each panning method were screened for expression of VHHs that bound to ciBoNT/B1. A total of 55 VHHs that appeared to be unique based on DNA fingerprinting were selected for DNA sequencing to identify VHHs that derive from common B cell precursors based on homology within the CDRs. From this information, 21 unique VHHs were selected for expression and characterization. Following characterization, 15 clonally independent groups were identified. The [Figure S1A](#SD1){ref-type="supplementary-material"} shows the sequences of 17 unique selected VHH, including two pair of apparently related VHHs (JLK-G12 and JLO-G11; JLI-G10 and JFM-A11), which derive from different libraries ([Table S1](#SD1){ref-type="supplementary-material"}). The monomeric VHH coding DNAs were initially expressed and purified as His~6~-tagged recombinant *Escherichia coli* thioredoxin (Trx) fusions with a carboxy-terminal E-tag, as previously described ([@R42]).

LCH~N~/A (M1--K871) was amplified from catalytically inactive BoNT/A that carries three mutations (E224Q/R363A/Y366F) ([@R25]) and cloned into pCDF-duet vector following an N-terminal His~6~ tag and a PreScission cleavage site. Rat Syt II (M1--I61) ([@R27]), Syt II (M1--C90), LC/A (P2--K438), H~C~B (E859--E1291) ([@R27]), ciA-B5, three anti-BoNT/B1 VHHs (JLK-G12, JLI-H11, and JLI-G10), and D12/11/B5 were cloned into pGEX-6P-1 for expression following the N-terminal GST and a PreScission cleavage site. Two anti-BoNT/A1 VHHs (ciA-D12 and ciA-H7) were cloned into pGEX-4T-2 vector following the N-terminal GST and a thrombin cleavage site. To facilitate co-expression of H~C~B and VHHs, three anti-BoNT/B1 VHHs (JLK-G12, JLI-H11, and JLO-G11) were additionally cloned into pAC28 vector following the N-terminal His~6~ tag ([@R29]). H~N~A, H~N~A S622C/V653C (H~N~A^DS^), ALc-B8 and ciA-F12 were expressed and purified as described previously ([@R25]; [@R33]; [@R58]).

His~6~-LCH~N~/Ai was expressed in the *E. coli* strain BL21-RIL (DE3) (Agilent). Transformed bacteria were grown at 37°C in TB medium in the presence of spectinomycin and chloramphenicol. Expression was induced with 0.1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) when OD~600~ reached \~1.0. Temperature was then decreased to 25°C and expression was continued for 16 hr. Syt II (1--61), Syt II (1--90), LC/A, H~C~B, ciA-B5, ciA-D12, ciA-H7, and D12/11/B5 were expressed in *E. coli* strain BL21-Star (DE3) (Invitrogen). GST-tagged JLK-G12, JLI-H11, and JLI-G10 were expressed in the *E. coli* strain Origami B (DE3) (Novagen). GST-tagged H~C~B was co-expressed with His-tagged JLK-G12, JLI-H11, or JLO-G11 in *E. coli* strain BL21-Star (DE3). Bacteria were cultured at 37°C in LB medium containing ampicillin and/or kanamycin. Temperature was reduced to 18°C when OD~600~ reached \~0.6. Expression was induced with 1 mM IPTG and continued at 18°C for 16 hr. Cells were harvested by centrifugation and stored at −20°C until use.

For protein purification, bacteria were re-suspended in a buffer containing 50 mM Tris (pH 8.0), 400 mM NaCl, and 0.4 mM PMSF and lysed by sonication. His~6~--LCH~N~/A was purified using a Ni-NTA (nitrilotriacetic acid, QIAGEN) affinity column in the same buffer supplemented with 20 mM imidazole and subsequently eluted with 250 mM imidazole. The eluted proteins were pooled followed by His-tag removal using PreScission protease and dialysis at 4°C against a buffer composed of 20 mM sodium acetate (pH 4.3) and 100 mM NaCl. This protein was further purified by MonoS ion-exchange chromatography (GE Healthcare) in a buffer containing 20 mM sodium acetate (pH 4.3) and eluted with a NaCl gradient, followed by Superdex-200 size exclusion chromatography (SEC; GE Healthcare) in 150 mM NaCl and 10 mM HEPES (pH 7.5).

All GST-tagged proteins were purified using Glutathione Sepharose 4B resins (GE Healthcare) in 50 mM Tris (pH 8.0), 400 mM NaCl, and eluted from the resins after on-column cleavage using either PreScission protease (H~C~B, LC/A, ciA-B5, D12/11/B5, JLK-G12, JLI-H11, and JLI-G10) or thrombin (ciA-H7 and ciA-D12). Uncleaved GST-tagged proteins (Syt II (1--61), Syt II (1--90), and GST-F12) were eluted in the same buffer supplemented with 20 mM reduced glutathione. The proteins were further purified by Superdex-200 Increase or Superdex-75 SEC in 10 mM HEPES (pH 7.4) and 150 mM NaCl. The complexes of H~C~B with JLK-G12, JLI-H11, or JLO-G11 were purified by Ni-NTA column, separately, followed by GST affinity column, on-column GST cleavage using PreScission protease, and Superdex-200 Increase SEC (150 mM NaCl, 10 mM HEPES, pH 7.4). The H~C~B--JLI-G10 complex was made by mixing the purified H~C~B and JLI-G10 at a molar ratio of 1:1.5 for 1 hr on ice, followed by purification using Superdex-200 Increase SEC (10mM HEPES, pH 7.4, and 150 mM NaCl). The LCH~N~/A--B5--D12--H7 complex or the LCH~N~/A--D12/11/B5--H7 complex was assembled by mixing the purified LCH~N~/A with the purified VHHs or VNA at a molar ratio of 1:1.5 for 1 hr on ice. The complexes were further purified by Superdex-200 Increase SEC (150 mM NaCl and 10 mM HEPES, pH 7.4). Each protein was concentrated to \~5 mg/ml using Amicon Ultra centrifugal filters (Millipore) and stored at −80°C until further characterization or crystallization.

All VHH heterodimer VNAs coding DNAs were synthesized (Genscript) and expressed either as cytosolic Trx fusion proteins in *E. coli*, or as secreted proteins in mammalian cells. Bacterial expression, purification, and quantification were performed as previously described ([@R42]). VNAs used in the mouse studies reported in this work were expressed by mammalian cells and purified from conditioned media by standard nickel affinity methods (Genscript). The purified proteins were analyzed by SDS-PAGE and western blot and shown to have over 95% purity. Quantification was by Bradford assay with BSA standards.

### Pull down assay {#S15}

To examine the interaction between H~C~B and rat Syt II (1--61), 20 μg of GST--Syt II (1--61) was immobilized on GST resins as the bait in a buffer containing PBS and 0.01% Tween 20. H~C~B (300 nM) or H~C~B pre-incubated with 600 nM of JLI-G10, JLK-G12, or JLI-H11 was pull-down as the preys at 8°C for 1 hr. After washing with the same buffer for three times, samples were boiled with SDS loading dye and analyzed by SDS-PAGE. The pull-down assay between H~C~B and Syt II (1--90) was performed using the same protocol, except that the buffer contained PBS and 0.5% Triton X-100 in the presence or absence of \~60 μM of GT1b. The pull-down samples were boiled with SDS loading dye supplemented with 4 M Urea.

### Liposome co-sedimentation assay {#S16}

Large unilamellar vesicles (LUV) were prepared as previously described ([@R33]). Briefly, lipids (1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) and 1-palmitoyl-2-(9,10-dibromostearoyl)phosphatidylcholine (BrPC)) (Avanti Polar Lipid) were dissolved in chloroform while GT1b trisodium salt (Santa Cruz Biotechnology) was dissolved in methanol. The lipids at the indicated molar ratios were mixed and then dried under nitrogen gas and placed under vacuum for overnight. The dried lipids were rehydrated and subjected to 5--10 rounds of freezing and thawing cycles. Liposomes were prepared by extrusion through a 200 nm pore membrane using an Avanti Mini Extruder according to the manufacturer's instructions.

The H~C~B--GT1b binding experiment was conducted by mixing 1 μM of H~C~B or H~C~B pre-incubated with 2 μM of VHH (JLI-G10, JLK-G12, or JLI-H11) with \~80 μg of liposomes composed of 70/20/10 mol% of BrPC/DOPS/GT1b. The protein--liposome mixture was then incubated in a buffer containing 50 mM NaCl, 20 mM MES (pH 6.5) at room temperature for 30 min followed by spinning progressively at 4,000 × , 9,000 × , and 16,000 × g for 30 min each. Supernatant and pellet were separated and analyzed by SDS-PAGE.

To study the effect of ciA-B5 on H~N~A--lipid interaction, H~N~A (25--200 nM) or H~N~A pre-bound with ciA-B5 at 1:1.5 molar ratio, was incubated with \~45 μg of liposomes composed of 80/20 mol% of BrPC/DOPS in a buffer containing 100 mM NaCl and 50 mM sodium acetate (pH 4.6) at room temperature for 1 hr. In some experiments, the H~N~A-bound liposomes were further mixed with ciA-B5 for 1 hr and centrifuged.

To further characterize the ciA-B5--H~N~A-liposome association, the centrifuged pellet of liposomes incubated with 100 nM of H~N~A or H~N~A--ciA-B5 complex was re-suspended in a buffer containing either PBS, or 1 M NaCl and 50 mM sodium acetate (pH4.6), or 0.15 M NaCl and 50 mM CAPS (pH 11), or 2% Triton X-100 ([@R55]), before another round of centrifugation.

### Calcein dye release assay {#S17}

Dried lipid containing 90/10 mol% of asolectin/cholesterol was resuspended in 150 mM NaCl, 20 mM HEPES (pH 7.0), 1 mM EDTA, and 50 mM calcein. Free calcein dye was separated from calcein-entrapped liposomes by desalting (Zeba). Fluorescence was measured on a Spectramax M2e cuvette module with excitation at 493 nm and emission at 525 nm. In the assay, liposomes were diluted in 150 mM NaCl, 20 mM sodium acetate (pH 4.6), 1 mM EDTA to give a final concentration of 0.1 mM and incubated until the fluorescence signal was stable. H~N~A or H~N~A pre-incubated with ciA-B5 at a 1:1.5 molar ratio was added at 25--400 nM and the fluorescence intensity was recorded for 10 minutes. The reaction was stopped by adding 0.1% Trion X-100. The percentage of fluorescence change was calculated as (F -- F~initial~)/(F~final~ -- F~initial~). The initial rate of calcein dye release was deduced from the slope of the linear part of the curve. The experiments were repeated three times independently.

### Membrane depolarization assay {#S18}

Liposomes composed of 70/20/10 mol% of DOPC/DOPS/cholesterol were prepared in 200 mM NaCl, 1 mM KCl, and 10 mM HEPES (pH 7.0). To create a trans-positive membrane potential (+ 135 mV), liposomes were diluted in 200 mM KCl, 1 mM NaCl, and 10 mM sodium acetate (pH 4.6). Membrane potential was monitored using 6 μM ANS. Valinomycin was added at time 0 s to give a final concentration of 30 nM. At 180 s, 40 nM of H~N~A pre-incubated with 0--200 nM of ciA-B5 or H~N~A S622C/V653C (H~N~ADS) was added and the fluorescence intensity at 490 nm was monitored for 6 minutes with excitation at 380 nm. The reaction was stopped by adding 2 μM of gramicidin from *Bacillus anerinolyticus* (Sigma-Aldrich). The fluorescence change relative to the maximal change in the presence of gramicidin was calculated as (F -- F~initial~)/(F~final~ -- F~initial~). The experiments were repeated three times independently.

### 8-anilinonaphthalene-1-sulfonic acid binding assay {#S19}

LC/A, LC/A-VHH, or VHH was incubated at \~1 μM with 100 μM ANS for 15 min in either 50 mM sodium acetate (pH 4.0--5.6) or 50 mM Bis-Tris (pH 6--7). All buffers contained 100 mM NaCl. Fluorescence intensity were recorded at 25 °C using a Molecular Devices SpectraMax M2e spectrophotometer with excitation at 370 nm and emission at 478 nm. The fluorescence intensity was corrected by subtraction of background fluorescence from ANS in a buffer without protein. Error bars indicate SD of three replicate measurements.

The binding of ANS to H~N~A was carried out as previously described ([@R33]). Briefly, H~N~A, H~N~A--ciA-B5, or ciA-B5 was incubated at \~1.34 μM with 100 μM of ANS for 15 min in a buffer containing 100 mM NaCl and either 50 mM sodium acetate (pH 4--5.2) or 50 mM Bis-Tris (pH 6--7). The peak emission intensity at 466 nm was recorded.

### Thermal denaturation assay {#S20}

The thermal stability of LC/A or LC/A--VHH was measured using a fluorescence-based thermal shift assay on a StepOne real-time PCR machine (Life Technologies). LC/A with or without VHH were incubated for 30 min in a buffer containing 0.1 M NaCl and either 50 mM sodium acetate (pH 4--5.5) or 50 mM Bis-Tris (pH 6--6.5). Immediately before the experiment, the protein (1 μM) was mixed with the fluorescent dye SYPRO Orange (Sigma-Aldrich). The samples were heated from 20 °C to 90 °C in a standard ramp rate of 1.5°C/min. The midpoint of the protein-melting curve (T~m~) was determined using the analysis software provided by the instrument manufacturer. The experiment was performed in triplicate.

### Crystallization {#S21}

Initial crystallization screens were performed using a Gryphon crystallization robot (Art Robbins Instruments) and high-throughput crystallization screen kits (Hampton Research and QIAGEN). Extensive manual optimizations were performed at 18°C when proteins were mixed with reservoir solution at 1:1 ratio.

1.  The best single crystals of H~C~B--JLI-G10 were grown by the hanging-drop vapor diffusion method at a protein concentration of 5 mg/ml with a reservoir solution containing 15% PEG 20,000 and 0.1 M MES (pH 6.5).

2.  Crystals of H~C~B--JLK-G12 were obtained by the hanging-drop vapor diffusion method at a protein concentration of 4 mg/ml with a reservoir solution containing 0.2 M ammonium sulfate, 14% PEG 8,000, and 0.1 M MES (pH 6.0).

3.  Crystals of H~C~B--JLO-G11 were obtained by the sitting-drop vapor diffusion method at a protein concentration of 5 mg/ml with a reservoir solution containing 20% Ethanol and 0.1 M Tris (pH 8.5).

4.  Crystals of H~C~B--JLI-H11 were obtained by the sitting-drop vapor diffusion method at a protein concentration of 5 mg/ml with a reservoir solution containing 0.1 M KCl, 15% PEG 5,000 MME, and 0.1 M MES (pH 6.5).

5.  Crystals of LCH~N~/Ai--B5--D12--H7 were grown by the hanging-drop vapor diffusion method at a protein concentration of 5 mg/ml with a reservoir solution containing 11% PEG 20,000 and 0.1 M sodium cacodylate (pH 6.4). Micro-seeding was necessary to obtain single crystals. Despite extensive efforts, crystallization of other LCH~N~/Ai--VHHs complexes, such as LCH~N~/Ai--B5--F12 and LCH~N~/Ai--B5--F12-H7, and the H~N~A--ciA-B5 complex was not successful.

6.  Crystals of LCH~N~/Ai--D12/11/B5--H7 were obtained by the hanging-drop vapor diffusion method at a protein concentration of 3 mg/ml with a reservoir solution containing 13% PEG 20,000 and 0.1 M sodium cacodylate (pH 6.6).

### Data collection and structure determination {#S22}

All crystals were cryoprotected in their original mother liquor supplemented with 20%--25% (v/v) ethylene glycol. The X-ray diffraction data for the crystals of H~C~B--JLK-G12 and LCH~N~/Ai--B5--D12--H7 were collected at 100 K at beamline BL9-2 at the Stanford Synchrotron Radiation Lightsource (SSRL). All other data were collected at 100 K at the NE-CAT beamline 24-ID-E, Advanced Photon Source (APS). The data were processed with iMOSFLM ([@R4]) or XDS as implemented in RAPD (<https://github.com/RAPD/RAPD>) ([@R28]). Data collection statistics are summarized in [Table S2](#SD1){ref-type="supplementary-material"}. Structures of the H~C~B--JLI-G10, H~C~B--JLO-G11, H~C~B--JLK-G12, and H~C~B--JLI-H11 complexes were determined by molecular replacement using the Phaser software ([@R36]) with H~C~B (PDB: 2NM1) ([@R27]) and the homology models of JLI-G10, JLO-G11, JLK-G12, or JLI-H11 that were built based on a VHH in PDB 5L21 ([@R64]) as the search models. Structures of the LCH~N~/Ai--B5--D12--H7 and LCH~N~/A--D12/11/B5--H7 complexes were solved by molecular replacement with Phaser using LCH~N~/A (PDB: 3V0A) ([@R25]) and the homology models of ciA-B5, ciA-D12, and ciA-H7 as the search models. Manual model building and refinement were performed in COOT ([@R19]), PHENIX ([@R1]), and CCP4 suite ([@R61]) in an iterative manner. The refinement progress was monitored with the free R value using a 5% randomly selected test set ([@R8]). The structures were validated through MolProbity ([@R11]) and showed excellent stereochemistry. Structural refinement statistics are listed in [Table S2](#SD1){ref-type="supplementary-material"}. All structure figures were prepared with PyMol (<https://pymol.org/2/>).

### Gel filtration analysis {#S23}

Toxin fragment (LCH~N~/A or H~C~B) was incubated with various VHHs or VNAs at a toxin:VHH/VNA = 1:1 or 1:5 molar ratio in PBS at 4°C for 1 hr. The protein mixtures were then separated by Superdex-200 SEC in PBS.

### SNAP-25 endopeptidase assay {#S24}

LC/A (2--438) at 1 nM was pre-incubated with 10--100 nM VHH for 15 min and subsequently added to 5 μM of SNAP-25(80--206)-His~6~ in a buffer containing 20 mM HEPES (pH 7.4), 5 μM MgSO~4~, 5 μM ZnSO~4~, and 0.1% Tween20. After incubation at room temperature for 30 min, the reactions were stopped by mixing with SDS-loading dye and boiling for 5 min. The samples were subjected to SDS-PAGE analysis.

### Characterization of BoNT/B VHH binding and neutralization properties {#S25}

VHHs (E-tagged) were tested for binding to the various recombinant BoNT preparations (ciBoNT/B1, H~C~B, LC/B, etc) by standard ELISAs ([@R41]) using plates coated with 100 μl of 1 μg/ml of the protein, or by first coating plates with 5 μg/ml of a BoNT-binding VHH (myc tagged) followed by a blocking step and then capturing a 1 ug/ml BoNT preparation. Typically ELISAs started at 125 nM VHH and 1:5 dilutions were performed prior to detection with HRP-goat anti-E-tag (Bethyl). BoNT/B neutralization studies were done similar to those previously reported for VHHs binding to BoNT/A ([@R41]), but employing 1 nM BoNT/B treatments of primary neurons and detecting VAMP cleavage on western blots as a ratio of VAMP to SNAP25 (1:25,000 rabbit anti-SNAP25 combined with 1:1000 rabbit anti-VAMP (Millipore)) and detected with 1:10,000 HRP-goat anti-rabbit IgG (GE Healthcare). BoNT cleaved VAMP is not recognized by the anti-VAMP antibody, so the assay relies on the ratio of intact VAMP:SNAP25 as comparted to controls.

### Mouse toxin lethality assay {#S26}

Mouse lethality assays were performed similarly as previously described ([@R41]). Briefly, female CD1 mice 22--27 g each (Charles River Labs) were grouped to minimize inter-group weight variation. VHH and VNA proteins were diluted in PBS at 40 pmol per mouse. BoNT holotoxins were prepared separately in PBS + 0.2% gelatin (Sigma-Aldrich). For co-intoxication assay, VNA and BoNT were combined in a total volume of 250 μl and incubated at room temperature for 30 min prior to administration by intraperitoneal injection. For separated administration experiments, VNA was injected to mice via tail vein at 5, 30, or 60 minutes prior to administration of toxins by intraperitoneal injection. Mice were observed at least twice per day and scored for survival and clinical signs using the following rubric: mild abdominal paradox (score of 1); severe abdominal paradox (2); agonal respiratory pattern (3); lethargy (1); generalized body weakness (2); total body paralysis (lack of righting reflex, 3); and death (16). Progression of toxic signs and time to death were determined for each mouse and averaged within each treatment group.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S27}
---------------------------------------

All *in vitro* assays were performed in triplicate. For pulldown and liposome co-sedimentation assays ([Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, and [S7](#SD1){ref-type="supplementary-material"}), protein band intensities was quantified by software ImageJ and the data were reported as mean ± S.D..

DATA AND CODE AVAILABILITY {#S28}
--------------------------

Atomic coordinates and structure factors for H~C~B--JLI-G10, H~C~B--JLO-G11, H~C~B--JLK-G12, H~C~B--JLI-H11, LCH~N~/Ai--D12--B5--H7, and LCH~N~/Ai--D12/11/B5--H7 have been deposited in the Protein Data Bank under accession codes 6UHT, 6UL4, 6UFT, 6UC6, 6UI1, 6UL6, respectively.
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![Structures of H~C~B in Complex with JLI-G10, JLK-G12, or JLI-H11\
(A) A model illustrating the binding of H~C~B to ternary receptors: Syt II, disialoganglioside 1a (GD1a), and lipid membrane.\
(B) A model of H~C~B simultaneously bound with three VHHs. H~C~B is positioned in the same orientation as in (A).](nihms-1566843-f0002){#F1}

![VHHs JLI-G10, JLK-G12, and JLI-H11 Inhibit H~C~B Binding to Host Receptors\
(A) JLI-G10 occupies the ganglioside-binding pocket on H~C~B. H~C~B--JLI-G10 is superimposed with H~C~B--GD1a (PDB: 4KBB). GD1a is drawn in the line model. The JLI-G10-binding interface is colored cyan, whereas regions overlapping or non-overlapping with the GD1a-binding site are colored pink and magenta, respectively. Key residues on the CDR3 loop (orange illustration) that interact with the conserved ganglioside recognition motif are shown in sticks.\
(B) JLI-G10 and JLK-G12 inhibit the binding of H~C~B to GT1b-containing liposomes. H~C~B pre-bound with VHHs was incubated with liposomes containing 70/20/10 mol% BrPC/DOPS/GT1b. After liposomes were pelleted, H~C~B and VHHs in the input (I), supernatant (S), and pellet (P) fractions were analyzed by SDS-PAGE.\
(C) JLI-G10 (orange) occupies the H~C~-loop (cyan illustration) of BoNT/B1. Hydrophobic residues reported to be crucial for lipid interaction are indicated. The structure of the apo BoNT/B1 (PDB: 2NP0) is shown (white illustration) for comparison.\
(D) JLK-G12 and JLI-H11, but not JLI-G10, prevent H~C~B from binding to Syt II (1--61). Pull-down assay was performed using H~C~B as a prey and the GST-tagged Syt II (1--61) as a bait. After binding, the GST resins were washed three times and the bound proteins were released and subjected to SDS-PAGE.\
(E) JLI-G10 and JLK-G12 block the interaction of H~C~B to its ternary receptors. GST-tagged Syt II (1--90) was used as baits. Pull-down assay was done in a buffer containing 0.5% Triton X-100, with the addition of GT1b as indicated. These experiments were performed in triplicate. Uncropped images of gels and quantification of protein band intensities are shown in [Figures S7A](#SD1){ref-type="supplementary-material"}-[S7F](#SD1){ref-type="supplementary-material"}.\
(F) JLK-G12 binds at the Syt-binding site on H~C~B. The JLK-G12- and the Syt II-binding surfaces of H~C~B are colored cyan and magenta, respectively. The overlapping interface is colored pink. Note that residue F101 in the CDR3 loop of JLK-G12 (illustration) and F54 of Syt II (line) occupy the same hydrophobic pocket on H~C~B.\
(G) Superposition of H~C~B--JLI-H11 (cyan and purple) and H~C~B--Syt II complexes (white; PDB: 2NM1). Note that JLI-H11 creates a side-to-side clash (arrow) with the N terminus of Syt II (white illustration). See also [Figures S2](#SD1){ref-type="supplementary-material"}, [S3](#SD1){ref-type="supplementary-material"}, and [S6](#SD1){ref-type="supplementary-material"}.](nihms-1566843-f0003){#F2}

![VHH ciA-B5 Inhibits the Channel Formation of H~N~A\
(A) ciA-B5 occupies the membrane-interacting region on H~N~A. The putative transmembrane region is colored brown, and the BoNT-switch is highlighted in pink. The CDR1, 2, and 3 of ciA-B5 are colored in red, orange, and blue, respectively.\
(B) Calcein dye release assay. H~N~A(0--400 nM) was tested with liposomes loaded with 50 mM calcein at pH 4.6, in the presence or absence of ciA-B5. The rate of calcein dye release was determined based on the increase of fluorescence at 525 nm during excitation at 493 nm.\
(C) Membrane depolarization assay. Liposomes were polarized at a positive internal voltage by adding valinomycin in the presence of a transmembrane KCl gradient. Membrane potential was measured using the voltage-sensitive fluorescence dye ANS. After 3 min, H~N~A with various concentrations of ciA-B5 was added. The data are presented as ± SD; n = 3.\
(D) Liposome co-sedimentation assay. H~N~A(25--200 nM) or H~N~A pre-bound with ciA-B5 in 1:1.5 molar ratio was incubated with liposomes containing 80/20 mol% BrPC/DOPS. Alternatively, H~N~A was incubated with liposomes followed by co-incubation with ciA-B5 before centrifugation. After liposomes were pelleted, H~N~A and ciA-B5 in the input (I), supernatant (S), and pellet (P) fractions were analyzed by SDS-PAGE.\
(E) The pellet fraction of liposomes incubated with 100 nM of H~N~A or H~N~A--ciA-B5 was re-suspended in buffers containing either PBS, 1 M NaCl and 50 mM sodium acetate (pH4.6), 0.15 M NaCl and 50 mM CAPS (pH 11), or 2% Triton X-100. The re-suspended liposomes were re-centrifuged and the supernatant (S2) and pellet (P2) fractions were separated. These experiments were performed in triplicate and quantification of protein band intensities are shown in [Figures S7L](#SD1){ref-type="supplementary-material"}-[S7N](#SD1){ref-type="supplementary-material"}. Uncropped images of gels are shown in [Figures S7G](#SD1){ref-type="supplementary-material"}-[S7K](#SD1){ref-type="supplementary-material"}.\
See also [Figures S2](#SD1){ref-type="supplementary-material"}, [S4](#SD1){ref-type="supplementary-material"}, and [S6](#SD1){ref-type="supplementary-material"}.](nihms-1566843-f0004){#F3}

![VHH ciA-H7 Interferes with Low-pH-Triggered LC/A Unfolding\
(A) Structure of ciA-D12- and ciA-H7-bound LCH~N~/A. Only the BoNT LC domain is shown for clarity. The ciA-H7-, ciA-D12-, and ciA-F12-binding epitopes on LC/A are colored pink, orange, and blue, respectively. The corresponding secondary structures are labeled. VHHs ciA-H7 and ciA-D12 are drawn as cyan and green ribbons, respectively.\
(B) Thermal stability of LC/A, LC/A--ciA-D12, LC/A--ciA-H7, and LC/A--ciA-F12. The thermal stability of the proteins was measured using a fluorescence-based thermal shift assay on a StepOne real-time PCR system (ThermoFisher). Protein melting was monitored using a hydrophobic dye, SYPRP Orange (Sigma-Aldrich), as the temperature was increased in a linear ramp from 20°C to 90°C. The midpoint of the protein-melting curve (T~m~) was determined using software provided by the instrument manufacturer. The data are presented as mean ± SD; n = 3.\
(C) ANS fluorescence assay. LC/A (residues 2--438) at 0.5 mg/ml (0.98 mM) was incubated with equimolar ratio of VHH in a buffer containing either 50 mM sodium acetate (pH 4.0--6.0), sodium citrate (pH 6.0), or HEPES (pH 7.0). All buffers contain 100 mM NaCl and 100 mM ANS. The mean values of fluorescence intensity at 478 nm are shown. Error bar represents SD of three replicate experiments.\
See also [Figures S2](#SD1){ref-type="supplementary-material"}, [S4](#SD1){ref-type="supplementary-material"}, and [S6](#SD1){ref-type="supplementary-material"}.](nihms-1566843-f0005){#F4}

![Rational Design of VNAs to Allow Simultaneous Binding of the Parental VHHs to a Single Toxin Molecule\
(A and B) Inter-molecular distances between selected VHHs that target BoNT/A1 (A) and BoNT/B1 (B), respectively. The Cα atoms of the N- and C-terminal residues are shown in blue and red spheres, respectively.\
(C--E) Gel filtration analysis to distinguish simultaneous versus non-simultaneous binding VNAs. D12/11/B5 and D12/11/H7 (C) were examined using LCH~N~/A. G10/12/G12 and G12/5/G10 (D) and H11/20/G12 and H11/3/G12 (E) were examined using H~C~B. Elution profiles were shown for the toxin fragments in complex with the parental VHHs (top panel), designer VNAs with optimal spacers to allow simultaneous binding (middle panel), or control VNAs with spacers too short to allow simultaneous binding (bottom panel). The toxin fragments were incubated with parental VHHs at 1:1 molar ratio. The bivalent VNAs were tested at 1:1 (blue curve) or 1:5 (green curve) molar ratio. The elution profiles of the free VNAs are colored gray. The peak elution volumes of the monomeric VNA-toxin complex and the VNA alone are indicated by red and blue arrows, respectively.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1566843-f0006){#F5}

![BoNT/A1 Intoxication in Mice Is Prevented by Co-administration of the Designer VNAs\
Symptoms of BoNT/A1 intoxication and lethality were monitored following administration of bivalent VNAs (D12/11/B5, D12/11/H7, or H7/30/B5) or toxin only. Time to death is plotted as % survival following co-injection of the indicated dose of BoNT/A1 and VNAs in groups of five mice. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1566843-f0007){#F6}

![BoNT/B1 Intoxication in Mice Is Prevented by Co-administration of the Designer VNAs\
Symptoms of BoNT/B1 intoxication and lethality were monitored following administration of bivalent VNAs G10/12/G12, G12/5/G10(A), H11/20/G12, H11/3/G12 (B), or toxin only. Time to death is plotted as % survival following co-injection of the indicated dose of BoNT/B and VNAs in groups of five mice. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1566843-f0008){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                                           SOURCE                                                               IDENTIFIER
  ------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------------------------------
  Antibodies                                                                                                                                                                         
  HRP-goat anti-E-tag                                                                                           Bethyl                                                               Cat\#:A190-132P; RRID: AB_345220
  Rabbit polyclonal anti-SNAP25                                                                                 EMD Millipore                                                        Cat\#: AB5871; RRID: AB_2192200
  Rabbit polyclonal anti-VAMP                                                                                   Millipore                                                            Cat\#: AB5856; RRID: AB_92090
  HRP-goat-anti-rabbit IgG                                                                                      GE Healthcare                                                        Cat\#: NA935; RRID: AB_772207
  Bacterial and Virus Strains                                                                                                                                                        
  *E. coli* BL21 Star (DE3)                                                                                     Invitrogen                                                           Cat\#: C6010-03
  *E. coli* BL21-CodonPlus(DE3)-RIL                                                                             Agilent Technologies                                                 Cat\#: 230245
  *E. coli* Origami B                                                                                           Novagen                                                              Cat\#: 70837-3
  Biological Samples                                                                                                                                                                 
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                                      
  Precision Protease                                                                                            This Paper                                                           N/A
  Human alpha-thrombin                                                                                          Haematologic Technologies                                            Cat\#: HCT-0020
  Inactive BoNT/B1                                                                                              This Paper                                                           N/A
  VNA D12/11/B5 ([@R41])                                                                                        Genscript                                                            N/A
  VNA D12/11/H7 ([@R41])                                                                                        Genscript                                                            N/A
  VNA H7/30/B5 ([@R41])                                                                                         Genscript                                                            N/A
  VNA G10/12/G12 ([Figure S1](#SD1){ref-type="supplementary-material"})                                         Genscript                                                            N/A
  VNA G12/5/G10 ([Figure S1](#SD1){ref-type="supplementary-material"})                                          Genscript                                                            N/A
  VNA H11/20/G12 ([Figure S1](#SD1){ref-type="supplementary-material"})                                         Genscript                                                            N/A
  VNA H11/3/G12 ([Figure S1](#SD1){ref-type="supplementary-material"})                                          Genscript                                                            N/A
  BoNT/A1                                                                                                       Metabiologics Inc.                                                   Cat\#: BoNT/A complex
  BoNT/B1                                                                                                       Metabiologics Inc.                                                   Cat\#: BoNT/B complex
  1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)                                                               Avanti Polar Lipid                                                   Cat\#: 850375C
  1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS)                                                             Avanti Polar Lipid                                                   Cat\#: 840035C
  1-palmitoyl-2-(9,10-dibromo)stearoyl phosphatidylcholine (BrPC)                                               Avanti Polar Lipid                                                   Cat\#: 850481C
  GT1b trisodium salt                                                                                           Santa Cruz Biotechnology                                             Cat\#: sc-221661
  Asolectin                                                                                                     Sigma-Aldrich                                                        Cat\#: 11145
  Cholesterol                                                                                                   Avanti Polar Lipid                                                   Cat\#: 700000
  Gramicidin                                                                                                    Sigma Aldrich                                                        Cat\#: G5002
  SYPRO Orange                                                                                                  Sigma Aldrich                                                        Cat\#: S5692
  Critical Commercial Assays                                                                                                                                                         
  Rneasy Kit                                                                                                    QIAGEN                                                               Cat\#: 74104
  Crystal Screen HT                                                                                             Hampton Research                                                     Cat\#: HR2-130
  SaltRx HT                                                                                                     Hampton Research                                                     Cat\#: HR2-136
  Index HT                                                                                                      Hampton Research                                                     Cat\#: HR2-134
  ProComplex Suite                                                                                              QIAGEN                                                               Cat\#: 130915
  Deposited Data                                                                                                                                                                     
  H~C~B--JLI-G10 structure                                                                                      PDB                                                                  6UHT
  H~C~B--JLK-G12 structure                                                                                      PDB                                                                  6UFT
  H~C~B--JLO-G11 structure                                                                                      PDB                                                                  6UL4
  H~C~B--JLI-H11 structure                                                                                      PDB                                                                  6UC6
  LCH~N~/Ai--B5--D12--H7 structure                                                                              PDB                                                                  6UI1
  LCH~N~/Ai--D12/11/B5--H7 structure                                                                            PDB                                                                  6UL6
  Experimental Models: Cell Lines                                                                                                                                                    
  Rat primary cerebellar neuron cultures                                                                        5-7d Spraque-Dawley rats                                             ([@R21])
  Experimental Models: Organisms/Strains                                                                                                                                             
  Female CD1 Mouse                                                                                              Charles River Labs                                                   Cat\#: CD1(ICR)
  Alpacas                                                                                                       Local farms                                                          N/A
  Oligonucleotides                                                                                                                                                                   
  LcH~N~(1--871)\_F: attactttcatatcttaaattcaatatagaagtattaataa tttacttaatatattcagtaaatgtagataataatctcagtaaatg   This Paper                                                           N/A
  LcH~N~(1--871)\_R: catttactgagattattatctacatttactgaatatattaa gtaaattattaatacttctatattgaatttaagatatgaaagtaat   This Paper                                                           N/A
  SytII(1--90)\_F: GGCCGGATCCATGAGAAACATCTTCAAG AGGAACCAG                                                       This Paper                                                           N/A
  SytII(1--90)\_R: GGCCGTCGACTTAGCACTTCTTACAGAT GCAGAAGC                                                        This Paper                                                           N/A
  LC/A(2--438)\_F: ctacttattgtatcctttatctaatgatttctatttagaagtt attatccctcttacacatagcaact                        This Paper                                                           N/A
  LC/A(2--438)\_R: agttgctatgtgtaagagggataataacttctaaatag aaatcattagataaaggatacaataagtag                        This Paper                                                           N/A
  Recombinant DNA                                                                                                                                                                    
  pCDF-duet-1                                                                                                   Novagen                                                              Cat\#: 71340
  pGEX-6p-1                                                                                                     GE Healthcare                                                        Cat\#: 28954648
  pGEX-4t-2                                                                                                     GE Healthcare                                                        Cat\#: 28954550
  Software and Algorithms                                                                                                                                                            
  iMOSFLM                                                                                                       ([@R4])                                                              <https://www.mrc-lmb.cam.ac.uk/mosflm/imosflm/ver730/introduction.html>
  XDS                                                                                                           ([@R28])                                                             <https://github.com/RAPD/RAPD>
  Phaser                                                                                                        ([@R36])                                                             <https://www.phenix-online.org/>
  Coot                                                                                                          ([@R19])                                                             <https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>
  Phenix                                                                                                        ([@R1])                                                              <http://www.phenix-online.org>
  CCP4                                                                                                          ([@R61])                                                             <http://www.ccp4.ac.uk/>
  Pymol                                                                                                         The PyMOL Molecular Graphics System, Version 1.7.Schrödinger, LLC.   <https://pymol.org/2/>
  Clustal Omega                                                                                                 ([@R51])                                                             <https://www.ebi.ac.uk/Tools/msa/clustalo/>
  ESPript 3.0                                                                                                   ([@R45])                                                             <http://espript.ibcp.fr/ESPript/ESPript/>
  PDBe-PISA                                                                                                     ([@R31])                                                             <https://www.ebi.ac.uk/pdbe/pisa/>
  Graphpad v7.2                                                                                                 Prism                                                                <https://www.graphpad.com/scientific-software/prism/>

###### Highlights

-   Crystal structures of six VHHs that bind and neutralize BoNT/A1 or BoNT/B1

-   Three VHHs inhibit the membrane insertion or the light chain unfolding of BoNT/A1

-   Three VHHs block the synaptotagmin, ganglioside, and/or lipid binding of BoNT/B1

-   Rationally designed bifunctional VHH heterodimers show superior antitoxin potency
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